Dare Bioscience Q1 FY26 net loss narrows 31% to $3 million

• Daré Bioscience posted a net loss of $3 million in the quarter ended March 31, 2026, narrowing 31% from a year earlier as revenue rose to $152,455 from research and development services and royalties.
• Operating loss narrowed 35% to $3 million, while research and development expense fell 71% to $660,462; selling, general and administrative costs edged down 3% to $2.25 million.
• Cash and cash equivalents totaled $18.5 million at quarter-end, and the company said it expects that balance to fund operating needs into the fourth quarter of 2026.
• Ovaprene Phase 3 enrollment continued, with a May interim review by the data safety monitoring board recommending the study proceed without modification; the company expects to reach at least 2,500 menstrual cycles of exposure in 2026.
• For commercialization, Daré to PLAY Sildenafil Cream is expected to begin shipping and generating revenue in the third quarter of 2026, while Flora Sync LF5 vaginal probiotic suppositories are expected to become available in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001401914-26-000026), on May 14, 2026, and is solely responsible for the information contained therein.